Cardima Preparing For Pivotal AF Trials Of Revelation Ablation Catheter
This article was originally published in The Gray Sheet
Executive SummaryCardima will begin a 60-100 patient, 10-center pivotal atrial fibrillation trial of its Revelation cardiac ablation microcatheter pending FDA approval of the company's feasibility trial, according to an Oct. 23 release.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.